NASDAQ · MDCX
Healthcare · Biotechnology
$2.03
Down-$0.23 (-11.33%)
Updated Nov 4, 2026, 8:03 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MDCX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
MDCX closed at $2.03 after 21 trading sessions, down 74.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $1.95 | $2.12 | $1.90 | $2.03 | 26K |
| Nov 2, 2026 | $1.86 | $1.982 | $1.78 | $1.93 | 31.23K |
| Oct 30, 2026 | $2.17 | $2.1799 | $1.82 | $1.88 | 86.7K |
| Oct 29, 2026 | $2.48 | $2.48 | $2.1246 | $2.15 | 123.41K |
| Oct 28, 2026 | $2.50 | $2.6889 | $2.45 | $2.48 | 23.39K |
| Oct 27, 2026 | $2.50 | $2.6226 | $2.40 | $2.45 | 43.25K |
| Oct 26, 2026 | $2.53 | $2.63 | $2.41 | $2.51 | 38.65K |
| Oct 23, 2026 | $2.60 | $2.61 | $2.50 | $2.50 | 84.16K |
| Oct 22, 2026 | $2.70 | $2.7999 | $2.57 | $2.62 | 44.26K |
| Oct 21, 2026 | $2.71 | $2.9071 | $2.65 | $2.68 | 30.71K |
| Oct 20, 2026 | $2.60 | $2.93 | $2.56 | $2.72 | 92.12K |
| Oct 19, 2026 | $3.12 | $3.2327 | $2.55 | $2.655 | 99.36K |
| Oct 16, 2026 | $3.61 | $3.61 | $3.25 | $3.25 | 28.22K |
| Oct 15, 2026 | $3.09 | $3.6532 | $3.00 | $3.43 | 203.14K |
| Oct 14, 2026 | $3.08 | $3.25 | $2.9214 | $3.12 | 69.94K |
| Oct 13, 2026 | $3.54 | $3.6748 | $3.14 | $3.28 | 66.11K |
| Oct 12, 2026 | $4.20 | $4.69 | $3.58 | $3.58 | 125.04K |
| Oct 9, 2026 | $4.325 | $4.74 | $4.20 | $4.605 | 346.64K |
| Oct 8, 2026 | $5.75 | $5.775 | $4.705 | $5.095 | 291.21K |
| Oct 7, 2026 | $8.00 | $8.15 | $7.995 | $8.01 | 95.73K |
| Oct 6, 2026 | $8.27 | $8.47 | $7.90 | $7.96 | 21.08K |
The latest Smart Investors Daily articles mentioning MDCX.
Company
Market Activity
Research & News
MDCX research
Company profile and research snapshot.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 20, 2026 | D. Boral Capital | Buy | — |
| Mar 19, 2026 | D. Boral Capital | Buy | — |
| Mar 9, 2026 | D. Boral Capital | Buy | — |
| Dec 15, 2025 | D. Boral Capital | Buy | — |
| Nov 17, 2025 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 16, 2026
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic
Benzinga · Mar 9, 2026
Benzinga · Mar 9, 2026
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today
Benzinga · Feb 10, 2026
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MDCX.
